Armata Pharmaceuticals, Inc.
AMEX:ARMPBiotechnology
-$0.02 today
- Market cap
- $117.90M
- Beta
- 1.22
- P/E (TTM)
- -0.9
- EPS (TTM)
- -$7.74
Volume 0.09M
Average 0.07M
ARMP Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Armata Pharmaceuticals, Inc.AMEX: ARMP
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $3.46M rose 6.5% year over year, ahead of the -4.8% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 1.1% from the prior quarter. Over 3 fiscal years it compounded at +18.6% a year.
Context
- Selling, general & admin amounted to 253.0% of revenue in FY2025, down 1.8 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 1 analysts of $13.08M (+5.4%) for the fiscal year ending Dec 2026, a step up from the -5.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $3.46M+1.1% QoQ
- Last fiscal yearDec 2025
- $12.41M-5.9% YoY
- LTMMar 2026
- $12.62M-4.8% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 12.41M USD
- Year-over-year change
- -5.9%
- 4-year CAGR
- +10.6%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.41M | -5.9% |
| FY2024 | 2024-12-31 | 13.18M | +23.5% |
| FY2023 | 2023-12-31 | 10.68M | +43.6% |
| FY2022 | 2022-12-31 | 7.44M | -10.2% |
| FY2021 | 2021-12-31 | 8.28M | — |
Selling, General & Admin vs competitors
How ARMP compares with its peers on the latest reported figures
- ARMP's LTM Mar 2026 selling, general & admin of $12.62M is the lowest of the 2 companies compared; the peer median is $19.24M.
- Its year-over-year change of -4.8% is the highest of 2, against a peer median of -21.8%.
- Selling, general & admin amounts to 426.6% of revenue for ARMP, versus a peer median of 35.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $19.24M | -21.8% | -16.6% | 35.1% | |
| LTM Mar 2026 | $12.62M | -4.8% | +18.6% | 426.6% | |
| Peer median (excluding ARMP) | $19.24M | -21.8% | -16.6% | 35.1% | |
Competitors are the stored peer set for ARMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.47M | 5.51M | 4.53M | 5.17M | 4.9M |
| Cost of Revenue | 20.02M | 35.02M | 972K | 34.43M | 1.53M |
| Gross Profit | (15.54M) | (29.51M) | 3.56M | (29.25M) | 3.37M |
| Gross Margin | -347.4% | -535.7% | 78.5% | -565.4% | 68.8% |
| Research & Development | 20.02M | 35.02M | 33.77M | 34.43M | 23.72M |
| Selling, General & Admin | 8.28M | 7.44M | 10.68M | 13.18M | 12.41M |
| Operating Expenses | 8.28M | 7.44M | 44.45M | 13.18M | 34.6M |
| Depreciation & Amortization | 1.17M | 892K | 972K | 1.33M | 1.53M |
| EBITDA | (21.92M) | (36M) | (65.45M) | (6.85M) | (155.68M) |
| EBITDA Margin | -490.0% | -653.5% | -1445.1% | -132.4% | -3174.5% |
| Operating Income | (23.82M) | (36.95M) | (40.89M) | (42.44M) | (31.22M) |
| Operating Margin | -532.5% | -670.8% | -902.8% | -820.2% | -636.7% |
| Interest Income | 5K | 29K | 179K | 697K | 388K |
| Interest Expense | 64K | 29K | 2.63M | 10.74M | 16.59M |
| Other Income / Expenses | 667K | 29K | (28.16M) | 23.52M | (142.58M) |
| Income Before Tax | (23.16M) | (36.92M) | (69.05M) | (18.92M) | (173.8M) |
| Pre-Tax Margin | -517.5% | -670.2% | -1524.5% | -365.6% | -3544.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (23.16M) | (36.92M) | (69.05M) | (18.92M) | (173.8M) |
| Net Margin | -517.5% | -670.2% | -1524.5% | -365.6% | -3544.0% |
| EPS (Basic) | (0.96) | (1.08) | (1.91) | (0.52) | (4.80) |
| EPS (Diluted) | (0.96) | (1.08) | (1.91) | (0.52) | (4.80) |
| Weighted Avg Shares | 24.1M | 34.29M | 36.08M | 36.16M | 36.24M |
| Weighted Avg Shares (Diluted) | 24.1M | 34.29M | 36.08M | 36.16M | 36.24M |
Armata Pharmaceuticals, Inc.
AMEX:ARMP
Intrinsic Alpha fair value
Locked
Current Price
$3.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.